ArticleESMO open2022

Who are the real high-risk patients with pathological T2N0M0 non-small-cell lung cancer that can benefit from adjuvant chemotherapy?

X Hou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.